Free Trial

Creative Medical Technology (CELZ) Competitors

Creative Medical Technology logo
$3.12 -0.01 (-0.16%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CELZ vs. MRSN, TPST, KZR, MAAQ, OKUR, GBIO, MIRA, MURA, MDCX, and RNTX

Should you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include Mersana Therapeutics (MRSN), Tempest Therapeutics (TPST), Kezar Life Sciences (KZR), Mana Capital Acquisition (MAAQ), OnKure Therapeutics (OKUR), Generation Bio (GBIO), MIRA Pharmaceuticals (MIRA), Mural Oncology (MURA), Medicus Pharma (MDCX), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

Creative Medical Technology vs. Its Competitors

Creative Medical Technology (NASDAQ:CELZ) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Creative Medical Technology has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. Creative Medical Technology's return on equity of -82.99% beat Mersana Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creative Medical TechnologyN/A -82.99% -79.49%
Mersana Therapeutics -212.94%-990.16%-54.85%

Creative Medical Technology has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Creative Medical Technology has higher earnings, but lower revenue than Mersana Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creative Medical Technology$10K803.67-$5.49M-$3.18-0.98
Mersana Therapeutics$40.50M0.91-$69.19M-$14.62-0.50

Mersana Therapeutics has a consensus price target of $56.60, suggesting a potential upside of 669.02%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mersana Therapeutics is more favorable than Creative Medical Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creative Medical Technology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mersana Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 1.8% of Creative Medical Technology shares are held by insiders. Comparatively, 13.0% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Mersana Therapeutics had 22 more articles in the media than Creative Medical Technology. MarketBeat recorded 27 mentions for Mersana Therapeutics and 5 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.86 beat Mersana Therapeutics' score of 0.01 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creative Medical Technology
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mersana Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
14 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Mersana Therapeutics beats Creative Medical Technology on 9 of the 16 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELZ vs. The Competition

MetricCreative Medical TechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.02M$3.13B$5.71B$9.79B
Dividend YieldN/A2.21%3.77%4.10%
P/E Ratio-0.9820.9230.9125.28
Price / Sales803.67232.70404.2188.50
Price / CashN/A41.5625.2228.45
Price / Book0.869.779.536.01
Net Income-$5.49M-$54.74M$3.26B$265.34M
7 Day Performance6.68%8.37%4.66%2.89%
1 Month Performance12.45%7.94%5.35%1.61%
1 Year Performance-11.00%18.27%32.14%25.61%

Creative Medical Technology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELZ
Creative Medical Technology
1.9766 of 5 stars
$3.12
-0.2%
N/A-10.9%$8.02M$10K-0.985Short Interest ↓
MRSN
Mersana Therapeutics
4.1684 of 5 stars
$6.07
+1.7%
$130.00
+2,041.7%
-78.1%$29.76M$34.01M-0.41150Earnings Report
Analyst Revision
TPST
Tempest Therapeutics
2.2415 of 5 stars
$8.81
+10.0%
$30.00
+240.5%
-43.8%$29.50MN/A-0.6020Positive News
Earnings Report
KZR
Kezar Life Sciences
3.6741 of 5 stars
$3.90
-0.8%
$39.50
+912.8%
-35.3%$28.71M$7M-0.3660Earnings Report
Short Interest ↑
Analyst Revision
MAAQ
Mana Capital Acquisition
N/A$3.45
-10.9%
N/A+758.2%$28.03MN/A0.001High Trading Volume
OKUR
OnKure Therapeutics
3.4916 of 5 stars
$2.00
-1.5%
$32.33
+1,516.7%
N/A$27.43MN/A-0.38N/AEarnings Report
Analyst Revision
GBIO
Generation Bio
3.269 of 5 stars
$4.05
+0.2%
$80.00
+1,875.3%
-74.8%$27.21M$19.89M-0.38150Earnings Report
Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
MIRA
MIRA Pharmaceuticals
3.2581 of 5 stars
$1.47
+3.5%
$17.00
+1,056.5%
-22.3%$27.08MN/A-2.882Earnings Report
Short Interest ↓
MURA
Mural Oncology
3.0268 of 5 stars
$1.66
+7.1%
$12.00
+622.9%
-46.3%$26.85MN/A-0.19119High Trading Volume
MDCX
Medicus Pharma
1.9301 of 5 stars
$2.24
+13.7%
$23.50
+949.1%
N/A$26.74MN/A-1.67N/AEarnings Report
Analyst Revision
Gap Up
RNTX
Rein Therapeutics
N/A$1.18
+1.7%
N/AN/A$26.73MN/A-0.419Earnings Report

Related Companies and Tools


This page (NASDAQ:CELZ) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners